SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

SLV is trending amidst a sharp pullback, primarily driven by increased CME margin requirements that triggered liquidations. A significant portion of the community views this as a buying opportunity, pointing to an impending China export ban, strong industrial demand from AI and EVs, and a perceived disparity between physical and paper silver prices. Conversely, many contend the recent surge was an unsustainable run, anticipating further volatility.

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.

Aquestive Therapeutics Inc

Aquestive Therapeutics is experiencing heightened investor conversation as the FDA's decision date for its Anaphylm oral film rapidly approaches, with widespread optimism for the needle-free, highly portable epinephrine treatment. Community discussions center on the product's "game-changing" convenience and the potential for a significant short squeeze, actively countering skepticism from bearish positions.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences (GLSI) is trending due to impressive preliminary Phase 3 trial results showing an 80% reduction in breast cancer recurrence, alongside an extended insider lock-up signaling strong management confidence. This news has ignited intense community discussion about its low float, extremely high cost to borrow, and significant short interest, leading to widespread speculation of a substantial short squeeze and a potential multi-billion dollar valuation for its breast cancer therapy.

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical (RARE) is trending due to significant market volatility after its bone disease drug, setrusumab, failed to meet primary endpoints in recent Phase 3 trials. The community is actively debating whether the ensuing sharp share price decline is an overreaction, pointing to the company's existing portfolio of approved therapies and robust pipeline. High trading volume reflects strong investor engagement as participants assess the company's revised valuation and potential for a rebound.

Sprott Physical Silver Trust - Units

Sprott Physical Silver Trust ET

PSLV is trending as community discussion focuses on a looming "silversqueeze" driven by accelerating industrial demand from sectors like AI and EVs, coupled with reported restrictions on silver exports from major producers. Investors are actively debating a growing global physical silver shortage and its potential for significantly higher prices, viewing physically-backed trusts like PSLV as a key play against market manipulation.

TryHard Holdings Ltd. is a lifestyle entertainment company that operates in Japan offering a diverse range of services across the entertainment and hospitality sectors. It operates through the following business segments: Consultancy and management, Event curation, Sub-leasing and Restaurants. The Consultancy and management segment provides expert services to clubs, including operations, event management, and strategic support to enhance performance and engagement. The Event curation segment organize and produce own events, also provides a full suite of services, including event planning, construction, entertainment booking, event operation, and ticket sales. The Sub-Leasing segment acts as an intermediary between landlords and clubs. The Restaurants segment operates several restaurants. The company was founded on October 16, 2013 and is headquartered in Osaka, Japan.

TryHard Holdings Ltd.

TryHard Holdings Ltd. (THH) is trending due to its recent NASDAQ IPO as a Japanese lifestyle entertainment company, sparking highly speculative trading and extreme volatility. The community is sharply divided, with some anticipating a significant short squeeze given its low float and reported high ROE, while others actively label it a pump-and-dump scheme often promoted in social media groups. This clash of sentiment is driving intense discussion and rapid price movements.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending following its pivotal FDA approval of YARTEMLEA, marking its first commercial product and the only approved therapy for transplant-associated thrombotic microangiopathy (TA-TMA). Community sentiment is highly bullish, anticipating significant long-term value and a potential short squeeze, fueled by the immediate January 2nd launch and a strong financial position from its Novo Nordisk partnership. Investors are keenly awaiting further details, including pricing and commercial strategy, expected from the upcoming conference call.

BTQ Technologies Corp. engages in the business of post-quantum encryption. It focuses on applications to the blockchain industry. Its products include PQScale, Keelug, Kenting, Preon, QPoW, and QByte. The company was founded by Nicolas Roussy Newton on March 26, 2021 and is headquartered in Vancouver, Canada.

BTQ Technologies Corp

BTQ Technologies is generating significant conversation following the launch of its GPU-accelerated quantum emulator, QLEO, now compatible with NVIDIA CUDA-Q, which the community sees as a crucial step for adoption. Many investors are also highlighting recent insider buying by the CEO, emphasizing BTQ's potential to provide quantum-secure infrastructure for digital assets like Bitcoin and stablecoins. Despite current market volatility and pre-revenue status, the focus is on the long-term opportunity as the company positions itself to address emerging quantum threats.

NorthWestern Energy Group, Inc. engages in the provision of electricity and natural gas to customers in Montana, South Dakota, Nebraska, and Yellowstone National Park. It operates through the following segments: Electric, Natural Gas, and Other. The Electric segment is involved in the regulated electric utility business primarily providing generation, transmission, and distribution services to customers in the Montana and South Dakota jurisdictions. The Natural Gas segment focuses on the natural gas utility business primarily providing production, storage, transmission, and distribution services to customers in the Montana, South Dakota, and Nebraska jurisdictions. The company was founded in November 1923 and is headquartered in Sioux Falls, SD.

NorthWestern Energy Group Inc

Northwestern Corp.

Northwestern Corporation is trending due to recent favorable regulatory developments, including settlement agreements in Montana that are poised to increase electric and natural gas revenues. This positive fundamental news is driving significant community discussion, with multiple 'actionable trade alerts' circulating, highlighting bullish technical indicators and momentum. The broader context of NWE as a stable utility, offering dividend appeal and potential benefits from evolving energy policies, further fuels investor interest.

ImageneBio, Inc. is a clinical-stage biotechnology company that boldly imagines a world where patients can be free from the burden of grievous immunological/autoimmune and inflammatory (I&I) diseases. It focuses on the development of new medicines with differentiated profiles that can effectively control and change the course of I&I diseases for affected patients, treat their symptoms, and improve quality of life. The company was founded in February 2016, and is headquartered in San Diego, CA.

ImageneBio Inc.

ImageneBio, Inc.

ImageneBio (IMA) is trending due to highly divergent analyst ratings, with some initiating bullish coverage citing deep pipeline value and significant cash, while others warn of a long timeline to data and a lower valuation. The community is actively debating the company's substantial cash reserves and the long-term potential of its Phase 2b program for atopic dermatitis against the lack of near-term catalysts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is Vident International Equity Strategy ETF (VIDI) a Strong ETF Right Now?

Nebius Group’s (NBIS) shares climbed early Wednesday after the Dutch artificial intelligence infrastructure company announced plans for a new data center in New Jersey.Nebius was spun off from the publicly traded Yandex Group, the Dutch holding company of Russian Internet giant Yandex. It began trading on the Nasdaq on Oct. 21.&nbsp;The company said the new data center commissioned in New Jersey will have a capacity of up to 300 megawatts (MW) and will mark a major upgrade to its U.S. cloud computing capacity.The proposed facility will be developed in phases, with the first capacity expected to be completed as early as the summer of 2025.&nbsp;Nebius said the new data center will help it meet its previous guidance of 100 MW of installed capacity by the end of 2025, with the potential to accelerate beyond that if necessary to meet demand.Arkady Volozh, Nebius founder and CEO, said, “Our first major data center in the US clearly advances our strategic goal of expanding our footprint in the American market as we continue building Nebius into a leading global AI infrastructure provider.”According to the executive, the site can host dedicated large-scale instances.&nbsp;The company also announced incremental capacity additions at its existing colocation deployment in Kansas City and a new location in Iceland.&nbsp;With the tripling of capacity at Nebius’s first data center in Finland and potential deployments at new sites currently in the pipeline, the company said it is&nbsp;well-positioned to ramp up installed capacity in the U.S. and Europe during 2025.Nvidia Corp.’s (NVDA) latest 13F filings showed the AI stalwart owned 1.191 million shares of Nebius.A bullish watcher viewed the news as very “positive.”<stembedurl>https://stocktwits.com/PMT123/message/606854633</stembedurl>Another user warned short-sellers regarding a wipeout of their wealth<stembedurl>https://stocktwits.com/Deandalean/message/606855794</stembedurl>Nebius traded up 2.36% at $30.31 on Wednesday morning. The stock is up about 7% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/gorilla-tech-defies-market-downturn-buoyed-by-positive-news/cheZvi5R6a">Gorilla Tech Defies Market Downturn Buoyed By Positive News: Retail Thinks Stock Still Undervalued After 110% Gain In 2025</a>

A view of a data center. (Photo by Yui Mok/PA Images via Getty Images)

Nvidia-Backed Nebius Stock Rallies On Plans For New 300MW Data Center In New Jersey: Retail’s Elated

The proposed facility will be developed in phases, with the first capacity expected to be completed as early as the summer of 2025. 

Equity

The proposed facility will be developed in phases, with the first capacity expected to be completed as early as the summer of 2025. 


Dutch artificial intelligence infrastructure company Nebius Group’s (NBIS)&nbsp;Nasdaq-listed shares&nbsp;retreated on Wednesday after&nbsp;clocking a 22% gain over the past three sessions.Much of the upside came after artificial intelligence stalwart Nvidia Corp. (NVDA) disclosed in its recent 13F filing that it owned 1.19 million Nebius shares, amounting to a 16.1% stake, according to Finchat data.Nebius&nbsp;was&nbsp;spun off from the publicly traded Yandex Group, the Dutch holding company of Russian Internet giant Yandex. The company, comprising infrastructure and business units outside Russia, began trading on the Nasdaq on Oct. 21.The stock received a boost in early December when Nebius announced it had entered into definitive agreements for a $700 million private placement with a select group of institutional and accredited investors, including Accel, NVIDIA, and certain accounts managed by Orbis Investments.Nvidia’s confirmation of the stake through the 13F proved healthy for the stock.A Stocktwits <a href="https://stocktwits.com/StocktwitsPolls/message/604307177">poll</a> asked platform users what they thought would be the next big catalyst for&nbsp;<a href="https://stocktwits.com/symbol/NBIS">Nebius stock.</a>An overwhelming 67% of the 1,800 respondents said the earnings report due on Thursday will be the next catalyst. Twelve percent believed it would be “analyst coverage initiation,” while 14% chose “more institutional loading” as the next big trigger. Only 7% of the respondents think a “Microsoft contract” would do the job.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/nbis_stpoll_74b67d6566.png" alt="nbis-stpoll.png">On Stocktwits, retail sentiment toward the stock stayed ‘bullish’ (66/100), with the positive mood accompanied by a ‘high’ message volume.<figure class="image"><img style="aspect-ratio:628/107;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/nbis_sentiment_9a1dce23c8.png" alt="nbis-sentiment.png" width="628" height="107"><figcaption>NBIS sentiment and message volume February 19, as of 11:18 am ET | Source:&nbsp;Stocktwits</figcaption></figure>A bullish watcher said Nebius is a winner but suggested prudence calls for taking some profits after such a big run.<stembedurl>https://stocktwits.com/Tobes82/message/604804225</stembedurl>Another said Nebius will be Europe’s “champion infrastructure provider.”<stembedurl>https://stocktwits.com/Sworntosecrecy/message/604800545</stembedurl>Nebius’ fiscal year 2024 fourth-quarter earnings report is due before the market opens, and its earnings call is scheduled for 8 a.m. ET. Analysts, on average, expect the company to report a loss of $0.39 on revenue of $57.71 million for the quarter, according to Finchat.The stock traded 2.21% lower at $47 in late morning trading. It is up about 74% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/cinemark-stock-plunges-as-2024-q4-eps-miss-overshadows-record-revenue/ch5sTLmRw7">Cinemark Stock Plunges As Q4 EPS Miss Overshadows Record Revenue, Dividend Reinstatement: Retail Shrugs It Off</a>

After Nebius’ Nvidia-Fueled Rally, Most Retailers Expect Thursday’s Q4 Report To Be Next Big Catalyst

Nebius was spun off from the publicly traded Yandex Group, the Dutch holding company of Russian Internet giant Yandex. 

VIDI
WisdomTree Trust - WisdomTree Vident International Equity Fund

Feed

News

Sentiment

Fundamentals

Info

Latest VIDI News

VIDIWisdomTree Trust - WisdomTree Vident International Equity Fund